Benda Pharmaceutical Inc.(fka BPMA)

[umiak]

http://biz.yahoo.com/bw/080111/20080111005472.html?.v=1

Benda Enters Into Complementary Financial Advisory Agreements with CRT Capital Group LLC and EastGate Financial, Inc.
Friday January 11, 1:03 pm ET


HUBEI PROVINCE, China--(BUSINESS WIRE)--Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTCBB: BPMA - News), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, announced today that it has entered into a financial advisory agreement with CRT Capital Group LLC (“CRT”) to assist the Company in evaluating its strategic and financial alternatives, including M&A, joint venture, divestiture, spin-off, financing or other capital market transactions.
ADVERTISEMENT


The Company also entered into a financial advisory agreement with EastGate Financial, Inc. (“EastGate”), engaging EastGate to provide consulting and advisory services with respect to establishing an office in New York, advise the Company in applying for listing on the American Stock Exchange (“AMEX”) and assist in identifying and choosing an AMEX specialist firm. The agreement with EastGate is in coordination with and complementary to Benda’s strategic relationship with CRT.

“Entering into these new strategic relationships with CRT and EastGate is a watershed moment in our development into a leading pharmaceutical company, both in China and beyond,” stated Yiqing Wan, Benda Chairman and CEO. “CRT and EastGate both have deep experience in our space, and CRT’s demonstrated success in helping evolve one of our closest peer companies, American Oriental Bioengineering (NYSE: AOB - News), gives us the utmost confidence that the relationship will help us achieve each of our operational and financial goals.”

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.bendapharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer.

About CRT Capital Group LLC

CRT Capital Group LLC (www.crtllc.com) is a full-service institutional securities firm that provides capital markets, research and investment banking services to its corporate and institutional clients. CRT's professionals have significant experience assisting middle-market companies and institutional investors with a wide range of financial products and services.

About EastGate Financial, Inc.

EastGate Financial, Inc. (www.eastgatefinancial.com) is a financial services firm dedicated to providing advisory services for Corporate Growth Alternatives, for Funding and Financing Alternatives, and assessing Industry-specific opportunities to support companies, management teams and investors throughout the global business community. EastGate’s professionals specialize in providing clients the unique bridge between the United States and China.

Benda Investor Resources

Fact Sheet: http://files.shareholder.com/downloads/BPMA/151228937x
4452657x111082/95430c49-a77a-43c9-89ad-d6cc75cffc59/FactSheet.pdf

PowerPoint Presentation: http://files.shareholder.com/downloads/
BPMA/151228937x4452657x111087/35a10e95-f328-45ad-81ab-529f6cc1af6d/
Bendapresentation061107.pdf

Gendicine® Video: http://play.rbn.com/play.asx?url=shareholder/
shareholder/wmdemand/bendavideo.wmv&proto=mms?mswmext=.asx

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward looking statements if they comply with the requirements of the Act.



Contact:
After Market Support, LLC
Justin K. Davis, 888-221-BPMA (2762)
[e-mail]

--------------------------------------------------------------------------------
Source: Benda Pharmaceutical, Inc.